Compare · NRXS vs TMDX
NRXS vs TMDX
Side-by-side comparison of Neuraxis Inc. (NRXS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRXS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.96B, about 49.5x NRXS ($59.8M).
- TMDX has been more active in the news (5 items in the past 4 weeks vs 4 for NRXS).
- TMDX has more recent analyst coverage (20 ratings vs 0 for NRXS).
- Company
- Neuraxis Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $59.8M
- $2.96B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 4
- 5
- Recent ratings
- 0
- 20
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest NRXS
- Amendment: SEC Form SCHEDULE 13D/A filed by Neuraxis Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.
- NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth
- SEC Form 10-Q filed by Neuraxis Inc.
- NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
- NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
- SEC Form 8-K filed by Neuraxis Inc.
- Chief Executive Officer Carrico Brian Allen bought $1,297 worth of shares (268 units at $4.84) (SEC Form 4)
- CRO, CCO, CPO Carrico Thomas Joeseph bought $1,588 worth of shares (328 units at $4.84) (SEC Form 4)
- Chief Financial Officer Henrichs Timothy Robert bought $9,375 worth of shares (1,937 units at $4.84) (SEC Form 4)
Latest TMDX
- Director Tobin James R sold $385,464 worth of shares (4,059 units at $94.97), decreasing direct ownership by 58% to 2,922 units (SEC Form 4)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Third Quarter 2026 Financial Results
- Officer Araujo Fernando N. was granted 22,969 shares (SEC Form 4)
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at Upcoming Investor Conferences
- TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Barclays initiated coverage on TransMedics Group with a new price target